Skip to main content

Laura Castellote Bellés

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Laura Castellote Bellés

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Efecto de la reposición de hierro sobre el remodelado ventricular después de la oclusi´pon coronaria transitoria en un modelo animal de ferropenia inducida por dieta

IP: José Antonio Barrabés Riu
Collaborators: Ignacio Ferreira González, David Aluja Gonzalez, Sara Delgado Tomás, Laura Castellote Bellés, Javier Inserte Igual
Funding agency: -Sociedad Española de Cardiologia
Funding: 15000
Reference: SEC/FEC-INV-BAS 23/11
Duration: 01/01/2024 - 31/12/2027

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: -
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Related news

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Related professionals

Judit Garriga Segarra

Judit Garriga Segarra

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Raquel Rodríguez Gil

Raquel Rodríguez Gil

Main researcher
Multidisciplinary Nursing Research Group
Read more
Ana Marti Delgado

Ana Marti Delgado

Tècnic/a Grau Superior
Communication Unit
Communication Directorate
Read more
Laura  Rey Sanchez

Laura Rey Sanchez

Research assistant
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.